← Back to Clinical Trials
Recruiting NCT06165653

NCT06165653 Guided Meditation During Radiation Therapy for Brain Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06165653
Status Recruiting
Phase
Sponsor University of Utah
Condition Brain Neoplasms
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2024-02-29
Primary Completion 2027-01-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
10 to 15-Minute, Audio-Recorded Guided Mediation Practice

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2024-02-29 with a primary completion date of 2027-01-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this interventional treatment study is to assess the anxiolytic effect of providing guided meditation during radiation treatment (RT) in patients with brain tumors. The main question it aims to answer is: • What is the change in acute anxiety in participants receiving the mindfulness intervention during radiation therapy compared to standard of care control conditions? Participants will be asked to participate in a 5-minute, audio-recorded mindfulness practice that will be played during the administration of each RT session. Researchers will compare this intervention to standard of care (no intervention) during RT.

Eligibility Criteria

Inclusion Criteria: * Participant aged ≥ 18 years. * Radiologically confirmed tumor of the brain. Note: Participants may have tumor resected after diagnosis. * Eligible to undergo radiation treatment for brain tumor for 25-33 treatments. * Willing to participate in either the guided meditation or standard of care control arm, regardless of treatment assignment. * Karnofsky performance score ≥ 60 or ECOG performance score ≤ 2. * MoCA mini score ≥ 11 * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: * Active suicidal ideation or active psychotic state in the opinion of the investigator. * An unstable illness that, in the opinion of the investigator, would interfere with study treatment. * Prior radiation therapy to the brain. * Inability to understand and/or speak the English language.

Contact & Investigator

Central Contact

Rachel Kingsford

✉ rachel.kingsford@hci.utah.edu

📞 801-585-0115

Principal Investigator

Lindsay Burt, MD

PRINCIPAL INVESTIGATOR

Huntsman Cancer Institute

Frequently Asked Questions

Who can join the NCT06165653 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06165653 currently recruiting?

Yes, NCT06165653 is actively recruiting participants. Contact the research team at rachel.kingsford@hci.utah.edu for enrollment information.

Where is the NCT06165653 trial being conducted?

This trial is being conducted at Salt Lake City, United States.

Who is sponsoring the NCT06165653 clinical trial?

NCT06165653 is sponsored by University of Utah. The principal investigator is Lindsay Burt, MD at Huntsman Cancer Institute. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology